Depreciation of Adaptimmune Therapeutics PLC from 30 Jun 2013 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Adaptimmune Therapeutics PLC quarterly and annual Depreciation in USD history and change rate from 30 Jun 2013 to 31 Mar 2025.
  • Adaptimmune Therapeutics PLC Depreciation for the quarter ending 31 Mar 2025 was $2,291,000, a 17% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Depreciation for 2024 was $10,814,000, a 14% increase from 2023.
  • Adaptimmune Therapeutics PLC annual Depreciation for 2023 was $9,453,000, a 80% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Depreciation for 2022 was $5,266,000, a 6.5% decline from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Adaptimmune Therapeutics PLC Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $2,291,000 -$480,000 -17% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q1 2024 $2,771,000 +$1,112,000 +67% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q1 2023 $1,659,000 +$273,000 +20% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q1 2022 $1,386,000 -$50,000 -3.5% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q1 2021 $1,436,000 -$275,000 -16% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $1,711,000 -$117,000 -6.4% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $1,828,000 +$88,000 +5.1% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q1 2018 $5,786,000 $1,740,000 +$754,000 +76% 01 Jan 2018 31 Mar 2018 10-Q 06 May 2019 2019 Q1
Q4 2017 $5,032,000 $1,614,000 +$778,000 +93% 01 Oct 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q3 2017 $4,254,000 $1,395,000 +$616,000 +79% 01 Jul 2017 30 Sep 2017 10-Q 02 Nov 2017 2017 Q3
Q2 2017 $3,638,000 $1,037,000 +$233,000 +29% 01 Apr 2017 30 Jun 2017 10-Q 03 Aug 2017 2017 Q2
Q1 2017 $3,405,000 $986,000 +$279,000 +39% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $3,126,000 $836,000 01 Oct 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
Q3 2016 $779,000 +$316,000 +68% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $804,000 +$507,000 +171% 01 Apr 2016 30 Jun 2016 10-Q 03 Aug 2017 2017 Q2
Q1 2016 $707,000 +$639,000 +940% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2017 2017 Q1
Q3 2015 $463,000 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $297,000 01 Apr 2015 30 Jun 2015 10-Q 08 Aug 2016 2016 Q2
Q1 2015 $68,000 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1

Adaptimmune Therapeutics PLC Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $10,814,000 +$1,361,000 +14% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $9,453,000 +$4,187,000 +80% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $5,266,000 -$364,000 -6.5% 01 Jan 2022 31 Dec 2022 10-K 24 Mar 2025 2024 FY
2021 $5,630,000 -$997,000 -15% 01 Jan 2021 31 Dec 2021 10-K 06 Mar 2024 2023 FY
2020 $6,627,000 -$545,000 -7.6% 01 Jan 2020 31 Dec 2020 10-K 06 Mar 2023 2022 FY
2019 $7,172,000 -$16,000 -0.22% 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
2018 $7,188,000 +$2,156,000 +43% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $5,032,000 +$1,906,000 +61% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2019 2018 FY
2016 $3,126,000 +$2,421,000 +343% 01 Jan 2016 31 Dec 2016 10-K 27 Feb 2019 2018 FY
2015 $705,000 +$465,000 +194% 01 Jul 2014 30 Jun 2015 10-K 15 Mar 2018 2017 FY
2014 $240,000 +$193,000 +411% 01 Jul 2013 30 Jun 2014 10-K 13 Mar 2017 2016 FY
2013 $47,000 01 Jul 2012 30 Jun 2013 8-K 08 Jul 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.